Investors Buy Large Volume of Call Options on Acurx Pharmaceuticals (NASDAQ:ACXP)

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the target of unusually large options trading activity on Tuesday. Stock investors acquired 4,128 call options on the stock. This represents an increase of approximately 17,848% compared to the average daily volume of 23 call options.

Acurx Pharmaceuticals Stock Performance

Shares of ACXP opened at $0.72 on Thursday. The stock has a market capitalization of $16.91 million, a P/E ratio of -1.03 and a beta of -1.38. The company’s fifty day moving average is $0.39 and its two-hundred day moving average is $0.59. Acurx Pharmaceuticals has a 1 year low of $0.30 and a 1 year high of $3.33.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. Sell-side analysts predict that Acurx Pharmaceuticals will post -0.89 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Acurx Pharmaceuticals in a research report on Thursday, May 15th.

Hedge Funds Weigh In On Acurx Pharmaceuticals

An institutional investor recently bought a new position in Acurx Pharmaceuticals stock. Vanguard Capital Wealth Advisors purchased a new position in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 67,500 shares of the company’s stock, valued at approximately $26,000. Vanguard Capital Wealth Advisors owned 0.30% of Acurx Pharmaceuticals as of its most recent SEC filing. 11.53% of the stock is currently owned by institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.